Effectiveness and safety of recombinant factor VII in pediatric cardiac surgery aged 13 years or less: A meta-analysis
Abstract
Objectives: Bleeding is the most serious complication of cardiac surgery among pediatric patients. Recombinant factor VII (rFVII) is a widely used coagulant, despite a lack of evidence on its effectiveness. The current study aimed to summarize the effectiveness and safety of using rFVII in pediatric cardiac surgery using data from existing double-arm studies.
Methods: After a systematic search of existing databases and careful scrutiny by two independent researchers, seven double-arm studies were shortlisted. Of these seven studies, there was one randomized control trial, one cohort study, and five case–control studies, which together had 1117 pediatric patients of cardiac surgery. rFVII was administered in the intervention arm group, whereas either a placebo or blood products were given to the control group for bleeding. Pooled risk ratio was the summary measure of association for thrombotic complications, reexploration, and mortality among the two groups. The standard mean difference was calculated for comparing mean chest tube output before and after the administration of rFVII between the two groups using the random-effects model. The heterogeneity coefficient was calculated for each outcome measure.
Results: No statistically significant difference was observed for mean chest tube output (before – [mean difference = 3.36, 95% confidence interval (CI) = −0.60, 7.31, P = 0.10] and after – [mean difference = −0.34, 95% CI = −0.26, 2.01, P = 0.78] administering rFVII), thrombotic complications (RR = 1.39, [95%] CI = 0.69–2.81) and mortality (relative risk [RR] = 1.19 [95%] CI = 0.82–1.74). However, the rate of reexploration was 1.86 times more in the intervention arm as compared to the control arm (RR = 1.86 (95%] CI = 1.16–2.98). There were insufficient data for length of stay in intensive care unit and hospital, and volumes of transfused blood for deriving summary measure.
Conclusions: The administration of rFVII does not provide any added advantage for bleeding control among pediatric patients of cardiac surgery. However, it increased the rate of reexploration among the intervention arm. However, due to the small sample sizes of the included studies, the results need to be taken cautiously.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).